Zongertinib in Previously Treated HER2-Mutant Non–Small-Cell Lung Cancer

• Published in: The New England journal of medicine Vol. 392; no. 23; pp. 2321 - 2333
• Main Authors: Heymach, John V., Ruiter, Gerrina, Ahn, Myung-Ju, Girard, Nicolas, Smit, Egbert F., Planchard, David, Wu, Yi-Long, Cho, Byoung Chul, Yamamoto, Noboru, Sabari, Joshua K., Zhao, Yanqiu, Tu, Hai-Yan, Yoh, Kiyotaka, Nadal, Ernest, Sadrolhefazi, Behbood, Rohrbacher, Maren, von Wangenheim, Ute, Eigenbrod-Giese, Sabina, Zugazagoitia, Jon
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 19.06.2025
• Subjects: Adult; Adverse events; Aged; Aged, 80 and over; Antibodies; Camptothecin - analogs & derivatives; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Carcinoma, Non-Small-Cell Lung - mortality; Critical Care; Critical Care General; Drug dosages; Epidermal growth factor; ErbB-2 protein; FDA approval; Female; Hematology; Humans; Hypotheses; Immunoconjugates - therapeutic use; Lung Cancer; Lung diseases; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Lung Neoplasms - mortality; Male; Metastases; Metastasis; Middle Aged; Mutants; Mutation; Non-small cell lung carcinoma; Oncology; Progression-Free Survival; Pulmonary; Receptor, ErbB-2 - antagonists & inhibitors; Receptor, ErbB-2 - genetics; Small cell lung carcinoma; Solid tumors; Trastuzumab - therapeutic use; Treatment Outcome; Treatments in Oncology; Tumors; Tyrosine Kinase Inhibitors - administration & dosage; Tyrosine Kinase Inhibitors - adverse effects
• ISSN: 0028-4793; 1533-4406; 1533-4406
• DOI: 10.1056/NEJMoa2503704

Among patients with tumors harboring tyrosine kinase domain mutations who received zongertinib (a selective inhibitor of the HER2 tyrosine kinase), 71% had a response, and median progression-free survival was 12.4 months.